Literature DB >> 22031903

The role of attenuated astrocyte activation in infantile neuronal ceroid lipofuscinosis.

Shannon L Macauley1, Milos Pekny, Mark S Sands.   

Abstract

Infantile neuronal ceroid lipofuscinosis (INCL) is an inherited neurodegenerative disorder affecting the CNS during infancy. INCL is caused by mutations in the CLN1 gene that lead to a deficiency in the lysosomal hydrolase, palmitoyl protein thioesterase 1 (PPT1). A murine model of INCL, the PPT1-deficient (PPT1(-/-)) mouse, is an accurate phenocopy of the human disease. The first pathological change observed in the PPT1(-/-) brain is regional areas of glial fibrillary acidic protein (GFAP) upregulation, which predicts future areas of neurodegeneration. We hypothesized that preventing GFAP and vimentin upregulation in reactive astrocytes will alter the CNS disease. To test this hypothesis, we generated mice simultaneously carrying null mutations in the GFAP, Vimentin, and PPT1 genes (GFAP(-/-)Vimentin(-/-)PPT1(-/-)). Although the clinical and pathological features of the GFAP(-/-)Vimentin(-/-)PPT1(-/-) mice are similar to INCL, the disease appears earlier and progresses more rapidly. One mechanism underlying this accelerated phenotype is a profound neuroinflammatory response within the CNS. Thus, our data identify a protective role for intermediate filament upregulation during astrocyte activation in INCL, a model of chronic neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22031903      PMCID: PMC3218425          DOI: 10.1523/JNEUROSCI.3579-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  43 in total

1.  Under stress, the absence of intermediate filaments from Müller cells in the retina has structural and functional consequences.

Authors:  Andrea Lundkvist; Andreas Reichenbach; Christer Betsholtz; Peter Carmeliet; Hartwig Wolburg; Milos Pekny
Journal:  J Cell Sci       Date:  2004-06-29       Impact factor: 5.285

2.  Cerebral protection by hypoxic preconditioning in a murine model of focal ischemia-reperfusion.

Authors:  B A Miller; R S Perez; A R Shah; E R Gonzales; T S Park; J M Gidday
Journal:  Neuroreport       Date:  2001-06-13       Impact factor: 1.837

3.  An improved cupric-silver method for impregnation of axonal and terminal degeneration.

Authors:  J S DeOlmos; W R Ingram
Journal:  Brain Res       Date:  1971-10-29       Impact factor: 3.252

4.  Infantile type of so-called neuronal ceroid-lipofuscinosis. 1. A clinical study of 15 patients.

Authors:  P Santavuori; M Haltia; J Rapola; C Raitta
Journal:  J Neurol Sci       Date:  1973-03       Impact factor: 3.181

Review 5.  Application of silver degeneration stains for neurotoxicity testing.

Authors:  R C Switzer
Journal:  Toxicol Pathol       Date:  2000 Jan-Feb       Impact factor: 1.902

Review 6.  Astrocyte intermediate filaments in CNS pathologies and regeneration.

Authors:  Milos Pekny; Marcela Pekna
Journal:  J Pathol       Date:  2004-11       Impact factor: 7.996

Review 7.  Is damage in central nervous system due to inflammation?

Authors:  A Chavarria; J Alcocer-Varela
Journal:  Autoimmun Rev       Date:  2004-06       Impact factor: 9.754

Review 8.  Astrocytes: biology and pathology.

Authors:  Michael V Sofroniew; Harry V Vinters
Journal:  Acta Neuropathol       Date:  2009-12-10       Impact factor: 17.088

9.  VEGF disrupts the neonatal blood-brain barrier and increases life span after non-ablative BMT in a murine model of congenital neurodegeneration caused by a lysosomal enzyme deficiency.

Authors:  Pampee P Young; Corinne R Fantz; Mark S Sands
Journal:  Exp Neurol       Date:  2004-07       Impact factor: 5.330

10.  Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis.

Authors:  Megan Griffey; Ellen Bible; Carole Vogler; Beth Levy; Praveena Gupta; Jonathan Cooper; Mark S Sands
Journal:  Neurobiol Dis       Date:  2004-07       Impact factor: 5.996

View more
  49 in total

Review 1.  Astrogliosis.

Authors:  Michael V Sofroniew
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-11-07       Impact factor: 10.005

Review 2.  Astroglial vesicular network: evolutionary trends, physiology and pathophysiology.

Authors:  R Zorec; V Parpura; A Verkhratsky
Journal:  Acta Physiol (Oxf)       Date:  2017-08-03       Impact factor: 6.311

3.  Resistin-Inhibited Neural Stem Cell-Derived Astrocyte Differentiation Contributes to Permeability Destruction of the Blood-Brain Barrier.

Authors:  Liu Xiaoying; Tian Li; Shang Yu; Jiang Jiusheng; Zhang Jilin; Wei Jiayi; Liu Dongxin; Fang Wengang; Zhao Xinyue; Yu Hao; Chen Yuhua; Shang Deshu
Journal:  Neurochem Res       Date:  2019-01-28       Impact factor: 3.996

Review 4.  Astrocytes and lysosomal storage diseases.

Authors:  K V Rama Rao; T Kielian
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

5.  Beneficial effects of gfap/vimentin reactive astrocytes for axonal remodeling and motor behavioral recovery in mice after stroke.

Authors:  Zhongwu Liu; Yi Li; Yisheng Cui; Cynthia Roberts; Mei Lu; Ulrika Wilhelmsson; Milos Pekny; Michael Chopp
Journal:  Glia       Date:  2014-07-15       Impact factor: 7.452

Review 6.  Why are astrocytes important?

Authors:  Alexei Verkhratsky; Maiken Nedergaard; Leif Hertz
Journal:  Neurochem Res       Date:  2014-08-12       Impact factor: 3.996

7.  Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice.

Authors:  Andrew W Kraft; Xiaoyan Hu; Hyejin Yoon; Ping Yan; Qingli Xiao; Yan Wang; So Chon Gil; Jennifer Brown; Ulrika Wilhelmsson; Jessica L Restivo; John R Cirrito; David M Holtzman; Jungsu Kim; Milos Pekny; Jin-Moo Lee
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

8.  Cell-Autonomous Regulation of Astrocyte Activation by the Circadian Clock Protein BMAL1.

Authors:  Brian V Lananna; Collin J Nadarajah; Mariko Izumo; Michelle R Cedeño; David D Xiong; Julie Dimitry; Chak Foon Tso; Celia A McKee; Percy Griffin; Patrick W Sheehan; Jeffery A Haspel; Ben A Barres; Shane A Liddelow; Joseph S Takahashi; Ilia N Karatsoreos; Erik S Musiek
Journal:  Cell Rep       Date:  2018-10-02       Impact factor: 9.423

9.  Oxidative stress as a therapeutic target in globoid cell leukodystrophy.

Authors:  Jacqueline A Hawkins-Salsbury; Elizabeth Y Qin; Adarsh S Reddy; Carole A Vogler; Mark S Sands
Journal:  Exp Neurol       Date:  2012-07-28       Impact factor: 5.330

Review 10.  Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.

Authors:  Shannon L Macauley
Journal:  Pediatr Endocrinol Rev       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.